Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals

Author:

Chen Yen-ChunORCID,Chang Te-ShengORCID,Chen Chien-Hung,Cheng Pin-Nan,Lo Ching-ChuORCID,Mo Lein-RayORCID,Chen Chun-Ting,Huang Chung-FengORCID,Kuo Hsing-TaoORCID,Huang Yi-HsiangORCID,Tai Chi-Ming,Peng Cheng-YuanORCID,Bair Ming-Jong,Yeh Ming-LunORCID,Lin Chih-Lang,Lin Chun-YenORCID,Lee Pei-Lun,Chong Lee-Won,Hung Chao-Hung,Huang Jee-FuORCID,Yang Chi-Chieh,Hu Jui-Ting,Lin Chih-Wen,Wang Chia-Chi,Su Wei-Wen,Hsieh Tsai-Yuan,Lin Chih-Lin,Tsai Wei-Lun,Lee Tzong-Hsi,Chen Guei-Ying,Wang Szu-JenORCID,Chang Chun-ChaoORCID,Yang Sheng-Shun,Wu Wen-ChihORCID,Huang Chia-Sheng,Hsiung Chou-Kwok,Kao Chien-Neng,Tsai Pei-ChienORCID,Liu Chen-HuaORCID,Lee Mei-Hsuan,Dai Chia-Yen,Kao Jia-HorngORCID,Chuang Wan-LongORCID,Lin Han-Chieh,Chen Chi-Yi,Tseng Kuo-ChihORCID,Yu Ming-LungORCID,

Abstract

To clarify the predictive factors of significant platelet count improvement in thrombocytopenic chronic hepatitis C (CHC) patients. CHC patients with baseline platelet counts of <150 × 103/μL receiving direct-acting antiviral (DAA) therapy with at least 12-weeks post-treatment follow-up (PTW12) were enrolled. Significant platelet count improvement was defined as a ≥10% increase in platelet counts at PTW12 from baseline. Platelet count evolution at treatment week 4, end-of-treatment, PTW12, and PTW48 was evaluated. This study included 4922 patients. Sustained virologic response after 12 weeks post-treatment was achieved in 98.7% of patients. Platelet counts from baseline, treatment week 4, and end-of-treatment to PTW12 were 108.8 ± 30.2, 121.9 ± 41.1, 123.1 ± 43.0, and 121.1 ± 40.8 × 103/μL, respectively. Overall, 2230 patients (45.3%) showed significant platelet count improvement. Multivariable analysis revealed that age (odds ratio (OR) = 0.99, 95% confidence interval (CI): 0.99–1.00, p = 0.01), diabetes mellitus (DM) (OR = 1.20, 95% CI: 1.06–1.38, p = 0.007), cirrhosis (OR = 0.66, 95% CI: 0.58–0.75, p < 0.0001), baseline platelet counts (OR = 0.99, 95% CI: 0.98–0.99, p < 0.0001), and baseline total bilirubin level (OR = 0.80, 95% CI: 0.71–0.91, p = 0.0003) were independent predictive factors of significant platelet count improvement. Subgroup analyses showed that patients with significant platelet count improvement and sustained virologic responses, regardless of advanced fibrosis, had a significant increase in platelet counts from baseline to treatment week 4, end-of-treatment, PTW12, and PTW48. Young age, presence of DM, absence of cirrhosis, reduced baseline platelet counts, and reduced baseline total bilirubin levels were associated with significant platelet count improvement after DAA therapy in thrombocytopenic CHC patients.

Funder

Kaohsiung Medical University

Kaohsiung Medical University Research Center Grant, Center for Liquid Biopsy and Cohort Research

Kaohsiung Medical University Hospital

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3